

Calciveyxol[®] 38



Infusion solution with
calcium gluconate,
boric acid and
magnesium chloride



- Good tissue tolerance
(also for subcutaneous
injection)
- Rapid effect
- Cardioprotective effect thanks
to the magnesium component





Hypocalcaemia frequently occurs in domesticated and farm animals and is often accompanied by other metabolic disorders.

The decisive advantage of calcium gluconate is its excellent tissue-tolerance. The solubility of calcium gluconate is increased by adding boric acid and, as a consequence, the necessary quantity of calcium can be administered in marginal volumes.

The animal's heart is protected against the cardiotoxic effects of calcium during intravenous application by the addition of magnesium.

Calciveyol® 38

Solution for infusion for slow intravenous use for cattle, pigs and sheep

Strongly hypertonic solution

Active substances and other ingredients

1 ml contains:

Active substances:

380.00 mg	calcium gluconate (Ph. Eur) (corresponding to Ca ²⁺ : 34.0 mg or 0.85 mmol, respectively)
60.00 mg	magnesium chloride hexahydrate (corresponding to Mg ²⁺ : 7.2 mg or 0.30 mmol, respectively)
50.00 mg	boric acid

Excipients:

Water for injections

Indications

Acute hypocalcaemic conditions.

As a supporting therapy for allergies, urticaria, haemorrhagic diathesis, uterine inertia.

Contraindications

- Hypercalcaemia and hypermagnesaemia
- Calcinosis in cattle and sheep
- Use following high dosages of vitamin D₃ preparations
- Chronic kidney insufficiency
- Simultaneous or shortly following intravenous application of inorganic phosphate solutions

Adverse reactions

Even when the therapeutic dosage is administered, a transient hypercalcaemia can develop due to the calcium content. This condition manifests itself as follows:

- initial bradycardia
- agitation, muscular tremors, salivation
- increased respiratory rate

The increase in the heart rate following initial bradycardia is to be taken as the sign of a beginning overdose. In this case the infusion must be stopped. Delayed side effects may occur in the form of disorders of the general condition and with symptoms of a hypercalcaemia even 6 – 10 hours after the infusion. They should not be incorrectly diagnosed as a recurrent hypocalcaemia.

See also "Overdose" under Special warnings.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon or pharmacist.

Target species

Cattle, pigs, sheep

Dosage for each species, routes and method of administration

For slow intravenous application.

Cattle:

Acute hypocalcaemic conditions:

20 – 30 ml Calciveyxo[®] 38 per 50 kg BW, intravenously
(equivalent to 0.34 – 0.51 mmol Ca²⁺ and 0.12 – 0.18 mmol Mg²⁺ per kg BW)

Supportive therapy for allergies, urticaria, haemorrhagic diathesis, uterine atony:

15 – 20 ml Calciveyxo[®] 38 per 50 kg BW, intravenously
(equivalent to 0.26 – 0.34 mmol Ca²⁺ and 0.09 – 0.12 mmol Mg²⁺ per kg BW)

Sheep, calf, pig:

3 – 4 ml Calciveyxo[®] 38 per 10 kg BW, intravenously
(equivalent to 0.26 – 0.34 mmol Ca²⁺ and 0.09 – 0.12 mmol Mg²⁺ per kg BW)

BW = body weight

The intravenous infusion must be given slowly over a period of 20 – 30 minutes. The specified dosages are standard values. They should always be adapted to the existing deficit and the particular condition of the circulatory system.

The first repeat treatment must not be carried out earlier than 6 hours after the initial treatment. Additional repeat treatments can be given at intervals of 24 hours, when it is assured that the persisting symptoms relate to a maintained hypocalcaemic condition.

Advice on correct administration

See "Special warnings"

Withdrawal period

Cattle, sheep:	Meat and offal	zero days
	Milk	zero days
Pigs:	Meat and offal	zero days

Special storage precautions

Keep out of the reach and sight of children.

Do not refrigerate or freeze. Protect from frost.

Consume content immediately. Dispose of residual content of the container.

Use only clear solutions from intact containers.

Do not use after the expiry date which is stated on the label and the outer carton.

Special warnings

Special precautions for use:

Special precautions for use in animals:

The intravenous application must be carried out slowly. During the infusion, the heart and circulation must be continuously monitored. In case of symptoms of overdosing (especially cardiac arrhythmia, fall in blood pressure, agitation), the infusion should be stopped immediately.

Interaction with other medicinal products and other forms of interaction:

Calcium increases the efficacy of heart glycosides. The cardiac effects of β -adrenergics and methylxanthines are amplified by calcium. Glucocorticoids increase the renal excretion of calcium by way of vitamin D-antagonism. Mixing with other medicinal products is to be avoided because of possible incompatibilities.

Overdose (symptoms, emergency procedures, antidotes), if necessary:

A too rapid rate of intravenous infusion or overdosing can lead to a hypercalcaemia (and/or hypermagnesaemia) with cardiotoxic symptoms such as tachycardia following initial bradycardia, cardiac arrhythmia and in severe cases ventricular cardiac fibrillation with cardiac arrest.

The following are to be observed as additional hypercalcaemic symptoms: motor weakness, muscular tremor, increased excitability, agitation, sweating, polyuria, drop in blood pressure, depression as well as coma. In these instances the infusion should be stopped immediately. Symptoms of a hypercalcaemia can also occur 6 – 10 hours after the infusion and must not be incorrectly diagnosed as recurrent hypocalcaemia due to the similarity of the symptoms.

Incompatibilities:

Mixing with other medicinal products is to be avoided because of possible incompatibilities.

Special precautions for the disposal of unused product or waste materials, if any
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Ask your veterinary surgeon how to dispose of medicines no longer required.

To be supplied only on veterinary prescription.

Package size

500 ml bottle

The information given in this product brochure conforms to the state of knowledge upon completion. Please read the package leaflet before using the veterinary medicinal product.

Veyx-Pharma is GMP- and QS-certified.

Veyx-Pharma GmbH · Soehreweg 6 · 34639 Schwarzenborn · Germany
Phone 0049 5686 99860 · Fax 0049 5686 1489 · E-Mail zentrale@veyx.de
www.veyx.com

05/2020